{"id":3885,"date":"2017-11-06T08:00:00","date_gmt":"2017-11-06T08:00:00","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/"},"modified":"2017-11-06T08:00:00","modified_gmt":"2017-11-06T08:00:00","slug":"ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/","title":{"rendered":"Ny djurstudie visar ytterligare f\u00f6rdelar med PharmaShell\u00ae"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>I Nanexas p\u00e5g\u00e5ende djurstudie har de f\u00f6rsta resultaten visat att en vidareutveckling av PharmaShell\u00ae teknologin minskar den initiala koncentrationstoppen avsev\u00e4rt.<\/strong><\/div>\n<p>I Nanexas tidigare djurstudie visades att plasmakoncentrationen av l\u00e4kemedel hos f\u00f6rs\u00f6ksdjuren efter en initialt h\u00f6gre koncentrationstopp kunde h\u00e5llas p\u00e5 konstant niv\u00e5 under de tre veckor som studien p\u00e5gick. Den initiala toppen kan vara av f\u00f6rdel i vissa sjukdomsbehandlingar medan det i andra fall d\u00e4remot \u00e4r \u00f6nskv\u00e4rt att minimera den f\u00f6r att direkt n\u00e5 en j\u00e4mn l\u00e4kemedelskonkoncentration i blodet.<\/p>\n<p>F\u00f6r att m\u00f6ta detta behov har Nanexa vidareutvecklat PharmaShell\u00ae och de f\u00f6rsta djurstudieresultaten med de optimerade PharmaShell\u00ae-skalen visar att den initiala koncentrationstoppen s\u00e4nkts med hela 85%.<\/p>\n<p>F\u00f6retagets VD David Westberg kommenterar<\/p>\n<p>De h\u00e4r resultaten \u00e4r viktiga f\u00f6r oss. Det visar att vi p\u00e5 ett kontrollerat s\u00e4tt kan styra plasmaprofilen av l\u00e4kemedel i blodet genom att variera vissa egenskaper hos PharmaShell\u00ae. Vi kan p\u00e5 s\u00e5 s\u00e4tt tillm\u00f6tesg\u00e5 de behov som l\u00e4kemedelsbolagen ser f\u00f6r att optimera behandlingseffekten i deras produktutvecklingsprojekt.<\/p>\n<p>L\u00e4kemedelsbolagen har specifikt efterfr\u00e5gat drug delivery-system som kan minimera den initiala koncentrationstoppen efter administering och med v\u00e5ra nya studieresultat hoppas jag att intresset f\u00f6r PharmaShell\u00ae kommer \u00f6kas ytterligare. Jag ser ocks\u00e5 med tillf\u00f6rsikt fram emot fler resultat fr\u00e5n samma djurstudie och ytterligare djurstudier \u00e4r ocks\u00e5 planerade inom den n\u00e4rmaste framtiden.&#34;<\/p>\n<p>F\u00f6r mer information kontakta:<br \/>David Westberg &#8211; VD, Nanexa AB (publ) Telefon: 0709 -42 83 03<br \/>E-post: david.westberg@nanexa.se www.nanexa.com<\/p>\n<p>Denna information \u00e4r s\u00e5dan information som Nanexa AB \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 6 november, 2017.<\/p>\n<p>Om Nanexa AB (publ)<\/p>\n<p>[image]<\/p>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug deliveryf\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae har Nanexa samarbetsavtal med bland andra AstraZeneca.\u00a0<\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"http:\/\/mb.cision.com\/Main\/12591\/2383346\/746631.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>I Nanexas p\u00e5g\u00e5ende djurstudie har de f\u00f6rsta resultaten visat att en vidareutveckling av PharmaShell\u00ae teknologin minskar den initiala koncentrationstoppen avsev\u00e4rt.<\/p>\n","protected":false},"template":"","class_list":["post-3885","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ny djurstudie visar ytterligare f\u00f6rdelar med PharmaShell\u00ae - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ny djurstudie visar ytterligare f\u00f6rdelar med PharmaShell\u00ae - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"I Nanexas p\u00e5g\u00e5ende djurstudie har de f\u00f6rsta resultaten visat att en vidareutveckling av PharmaShell\u00ae teknologin minskar den initiala koncentrationstoppen avsev\u00e4rt.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\\\/\",\"name\":\"Ny djurstudie visar ytterligare f\u00f6rdelar med PharmaShell\u00ae - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2017-11-06T08:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ny djurstudie visar ytterligare f\u00f6rdelar med PharmaShell\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ny djurstudie visar ytterligare f\u00f6rdelar med PharmaShell\u00ae - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/","og_locale":"sv_SE","og_type":"article","og_title":"Ny djurstudie visar ytterligare f\u00f6rdelar med PharmaShell\u00ae - Nanexa AB","og_description":"I Nanexas p\u00e5g\u00e5ende djurstudie har de f\u00f6rsta resultaten visat att en vidareutveckling av PharmaShell\u00ae teknologin minskar den initiala koncentrationstoppen avsev\u00e4rt.","og_url":"https:\/\/nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/","url":"https:\/\/nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/","name":"Ny djurstudie visar ytterligare f\u00f6rdelar med PharmaShell\u00ae - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2017-11-06T08:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/ny-djurstudie-visar-ytterligare-fordelar-med-pharmashell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Ny djurstudie visar ytterligare f\u00f6rdelar med PharmaShell\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}